Company intelligence / Profile preview

BioShai

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

BioShai is developing PDx, a simple blood test designed for the early diagnosis of Parkinson’s disease. The technology measures specific biomarkers in the blood to enable earlier and more accurate detection compared to current standards. Clinical results or regulatory status are not detailed in available sources.

Therapeutic areas: Neurology
Modalities: Diagnostic blood test (in vitro diagnostic)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

PDx

Pre-clinical

Indications: Parkinson's disease

Beyond the preview

Go deeper on BioShai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioShai.

Explore the full profile